Neurocrine Biosciences (NBIX) Total Liabilities (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Total Liabilities for 17 consecutive years, with $1.7 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Liabilities rose 39.31% year-over-year to $1.7 billion; the trailing twelve-month figure through Jun 2026 stood at $1.7 billion (up 39.31% YoY), and the FY2025 full-year result was $1.4 billion, up 22.09% from the prior year.
• Total Liabilities grew to $1.7 billion in Q2 2026 per NBIX's latest filing, from $1.5 billion in the prior quarter.
• Across five years, Total Liabilities topped out at $1.7 billion in Q2 2026 and bottomed at $582.3 million in Q2 2022.
• Historically, Total Liabilities has averaged $993.1 million across 5 years, with a median of $932.8 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Total Liabilities retreated 14.01% in 2022, then jumped 60.86% in 2024.
• Over 5 years, Total Liabilities stood at $660.9 million in 2022, then jumped by 54.24% to $1.0 billion in 2023, then rose by 10.75% to $1.1 billion in 2024, then advanced by 22.09% to $1.4 billion in 2025, then grew by 20.83% to $1.7 billion in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $1.7 billion, $1.5 billion, and $1.4 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.